Cullinan Therapeutics Inc (CGEM)

$7.49 -0.33 (-4.22%)
Market Cap 438.85M
Revenue (ttm) 0.00
Net Income (ttm) -167.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 573,000
Avg Vol 436,744
Day's Range N/A - N/A
Shares Out 58.51M
Stochastic %K 16%
Beta -0.05
Analysts Strong Sell
Price Target $32.14

Latest News on CGEM

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 5 weeks ago

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

Feb 24, 2025, 7:00 AM EST - 5 weeks ago

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

Jan 28, 2025, 7:00 PM EST - 2 months ago

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy

Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC

Jan 9, 2025, 11:11 PM EST - 3 months ago

Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

Jan 8, 2025, 5:26 PM EST - 3 months ago

Cullinan Therapeutics: Casting A Wide Net With Their Pipeline

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

Nov 14, 2024, 10:01 AM EST - 5 months ago

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

Nov 5, 2024, 7:00 AM EST - 5 months ago

Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

Nov 4, 2024, 7:00 AM EST - 5 months ago

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Oct 16, 2024, 7:00 AM EDT - 6 months ago

Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Sep 17, 2024, 7:00 AM EDT - 7 months ago

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Sep 14, 2024, 4:15 AM EDT - 7 months ago

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

Jun 1, 2024, 7:00 AM EDT - 10 months ago

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

May 24, 2024, 8:00 AM EDT - 11 months ago

Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

May 23, 2024, 5:04 PM EDT - 11 months ago

Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

May 15, 2024, 4:05 PM EDT - 11 months ago

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

Apr 24, 2024, 10:09 AM EDT - 1 year ago

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

Apr 16, 2024, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

Apr 16, 2024, 6:59 AM EDT - 1 year ago

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 14, 2024, 7:00 AM EDT - 1 year ago

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

Mar 1, 2024, 7:00 AM EST - 1 year ago

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

Cullinan Oncology to Participate in Upcoming Investor Conferences

Feb 27, 2024, 8:00 AM EST - 1 year ago

Cullinan Oncology to Participate in Upcoming Investor Conferences

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 18, 2023, 4:53 PM EST - 1 year ago

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Dec 14, 2023, 4:30 PM EST - 1 year ago

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Nov 8, 2023, 7:00 AM EST - 1 year ago

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Nov 3, 2023, 12:01 PM EDT - 1 year ago

Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Cullinan Oncology: Inexplicably Trading Below Cash Despite Robust Data

Sep 11, 2023, 11:57 AM EDT - 1 year ago

Cullinan Oncology: Inexplicably Trading Below Cash Despite Robust Data

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Aug 9, 2023, 7:00 AM EDT - 1 year ago

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Aug 3, 2023, 4:15 PM EDT - 1 year ago

REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Cullinan Oncology: Playing 'Moneyball' In The Drug Development Sector

Jun 28, 2023, 9:08 AM EDT - 1 year ago

Cullinan Oncology: Playing 'Moneyball' In The Drug Development Sector

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023

May 25, 2023, 5:00 PM EDT - 2 years ago

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 11, 2023, 4:01 PM EDT - 2 years ago

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results

Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023

Apr 26, 2023, 10:08 AM EDT - 2 years ago

Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023

Cullinan Oncology to Participate in Stifel's 2023 Targeted Oncology Days

Apr 20, 2023, 7:00 AM EDT - 2 years ago

Cullinan Oncology to Participate in Stifel's 2023 Targeted Oncology Days

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines

Mar 27, 2023, 7:00 AM EDT - 2 years ago

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines

Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting

Mar 14, 2023, 4:35 PM EDT - 2 years ago

Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 9, 2023, 7:00 AM EST - 2 years ago

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Cullinan Oncology to Participate in Cowen's 43rd Annual Health Care Conference

Feb 27, 2023, 8:00 AM EST - 2 years ago

Cullinan Oncology to Participate in Cowen's 43rd Annual Health Care Conference

Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed

Feb 13, 2023, 7:00 PM EST - 2 years ago

Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed

Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference

Feb 2, 2023, 4:01 PM EST - 2 years ago

Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 1, 2023, 4:42 PM EST - 2 years ago

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Jan 24, 2023, 8:00 AM EST - 2 years ago

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Nov 14, 2022, 7:00 AM EST - 2 years ago

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Cullinan Oncology Announces the Appointment of David P. Ryan, M.D.

Nov 2, 2022, 8:00 AM EDT - 2 years ago

Cullinan Oncology Announces the Appointment of David P. Ryan, M.D.

Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619

Oct 25, 2022, 7:00 AM EDT - 2 years ago

Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619

Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years

Sep 22, 2022, 6:16 AM EDT - 2 years ago

Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years

Cullinan Oncology: One Of The Leaders In Cancer Treatment Development

Sep 14, 2022, 2:45 PM EDT - 2 years ago

Cullinan Oncology: One Of The Leaders In Cancer Treatment Development

Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference

Sep 7, 2022, 8:00 AM EDT - 2 years ago

Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference

Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer

Aug 15, 2022, 4:57 PM EDT - 2 years ago

Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer